Wockhardt Limited. Investor Presentation By Dr. Murtaza Khorakiwala Managing Director Q1FY16

Transcription

1 Wockhardt Limited Investor Presentation By Dr. Murtaza Khorakiwala Managing Director Q1FY16

2 Safe Harbor Statement Except for historical information contained herein, statements in this communication, which include words or phrases such as will, aim, will likely result, would, believe, August, expect, will continue, anticipate, estimate, intend, plan, contemplate, seek to, future, objective, goal, likely, project, should, potential, will pursue and similar expressions or variations of such expressions August constitute forward looking statements. These forward looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. Wockhardt Limited does not undertake any obligation to update forward looking statements to reflect events or circumstances after the date thereof. Investor Presentation August

3 Introduction to Wockhardt Key Business Dynamics

4 Wockhardt Today Mexico USA UK, Ireland, France, Switz. India Direct Operations in India, USA and Europe Multi Ethnic workforce from 21 different Nationalities Wockhardt Direct operations ROW operations Investor Presentation August

5 Wockhardt Today Chicago Ireland UK 9 sites in India Baddi 12 Manufacturing Locations globally Formulations APIs Ankleshwar Daman (2 Plants) Aurangabad (5 Plants) Investor Presentation August

6 Wockhardt Today 3 R&D Centers worldwide USA / UK & India Investor Presentation August

7 Key Business Update

8 Key Business Update Regulatory Update US FDA has completed inspection in one of the manufacturing facility in Himachal Pradesh in July, 2015 and no 483 has been issued to the company. US FDA s inspection of Waluj facility completed during the quarter with minor observations. The Company s on going efforts towards compliance measures for Chikalthana and Waluj facilities continues to be in place. Resumed Supplies to UK from our Chikalthana Facility. Research Update Received the coveted Breakthrough discovery (QIDP) status for another NCE product WCK 4873 during the quarter. Previously 2 of its drug WCK 771 and WCK 2349 received QIDP status. QIDP status allows for fast track review by US FDA and also grants a five year extensions to the drug patents in USA. Wockhardt is the only Indian company to receive QIDP status for its NCE products. Got approval from US FDA for marketing 5mg/5ml of Oxycodone HCL liquid from MGP. Oxycodone is used extensively in management of pain, especially in opioid tolerant patients. Filed for 54 patents during the quarter taking the cumulative filings to 2322 and has been granted 26 patents during the quarter taking the cumulative patents granted to 367. Investor Presentation August

9 Q1FY16 Results

10 Sales Growth of 15% over Q1FY15 Rs.crore Growth of 15% in Q1FY16 over Q1FY15 Investor Presentation August

11 EBITDA Growth of 165% over Q1FY15 Rs.crore Growth of 165% in Q1FY16 over Q1FY15 Investor Presentation August

12 PAT Growth of 470% over Q1FY15 Rs.crore Growth of 470% in Q1FY16 over Q1FY15 Investor Presentation August

13 Research 13.3% of Sales in Q1FY16 Growth of 31% in Q1FY16 over Q1FY15 Investor Presentation August

14 Rs.cr. US Business Contributes 20% of Total Revenue $48 USA $36 Declines by 21% (26% in $ terms) over Q1FY15. During the Q1FY16, 5 ANDA s filed & 1 approval received cumulative ANDA s pending for approval is Q1-FY15 Q1-FY16 Investor Presentation August

15 Rs.cr. Rs.cr. EU Operations UK 37 UK Operations 1 New filing done and 1 New product launched in Q1FY UK operation Grows by 55% (grows by 59% terms) in 220 Q1FY Q1-FY15 Q1-FY Ireland Ireland Operations Ireland Declines by 11% (growth of 4% in terms) in Q1FY Q1-FY15 Q1-FY16 Investor Presentation August

16 Rs.cr. India & Emerging Markets India Business Grows by 27% for Q1FY new products in Q1FY16 launched in India. Emerging Market operations grew by 47% in Q1FY India & Emerging Markets (EM) 66 EM 97 EM India 375 India 0 Q1FY15 Q1FY16 Investor Presentation August

17 For investor updates and communication please visit For Information please contact Arun Khatanhar Tel.: Investor Presentation August